Axelopran is under clinical development by Theravance Biopharma and currently in Phase II for Opioid-Induced Constipation (OIC). According to GlobalData, Phase II drugs for Opioid-Induced Constipation (OIC) have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Axelopran’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Axelopran overview
It was under development for the treatment of hepatocellular carcinoma (HCC), renal cell carcinoma (RCC) and solid tumor.
Theravance Biopharma overview
Theravance Biopharma is a biopharmaceutical company that discovers, develops, and markets organ-selective medicines for the treatment of inflammation and immune system disorders and specializes in developing respiratory medicines. The company is investigating its pipeline candidates for the treatment of asthma; and neurogenic orthostatic hypotension (nOH). Theravance Biopharma has agreements with other pharmaceutical companies and holds economic interests in potential future payments made to Innoviva, Inc from Glaxo Group Limited or one of its affiliates. The company has subsidiaries in the US, Ireland, and the UK. Theravance Biopharma is headquartered in George Town, Cayman Islands, the UK.
For a complete picture of Axelopran’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
